Replay available

BICO Group AB (publ) (BICO) Q4 2025 Earnings Call

BICO Group AB (publ) (STO: BICO) Q4 2025 earnings conference call, held 2026-02-18. Replay captured from the company's public earnings webcast.

Wed, February 18, 2026 at 4:00 AMendedReplay
BICO Group AB (publ) (BICO) Q4 2025 Earnings Call

Hosted by

Featured presenters

Maria Fors

President and CEO

Jakob Thorndenberg

CFO

Ludvig Lundgren

Analyst, Nordia

Philip Einarsson

Analyst, Red Eye

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Bico Group Ab Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.996 Welcome to BICO Q4 2025 report presentation. 00:00:03.996 -- 00:00:08.162 For the first part of the presentation, participants will be in listen-only mode. 00:00:08.162 -- 00:00:12.687 During the questions and answers session, participants are able to ask questions by dialing 00:00:12.687 -- 00:00:17.273 pound key five on their telephone keypad. Now I will hand the conference over to the 00:00:17.273 -- 00:00:21.459 speakers, CEO Maria Force and CFO Jacob Thordenberg. 00:00:21.459 -- 00:00:23.980 Please go ahead. 00:00:26.018 -- 00:00:30.164 Hello and welcome to BiCo Group's Q4 2025 earnings call. 00:00:30.164 -- 00:00:35.190 I'm Maria Fors, President and CEO and I will together with BiCo's CFO Jakob Thorndenberg 00:00:35.190 -- 00:00:38.996 present this year's end report. Here's today's agenda. 00:00:38.996 -- 00:00:44.283 I will open today's session by summarizing 2025 and also describe how BiCo serves 00:00:44.283 -- 00:00:48.849 the world's leading pharma and biotech companies with solutions that transform how labs 00:00:48.849 -- 00:00:52.900 operate, innovate and solve our customer challenges. 00:00:52.900 -- 00:00:58.147 Following that, I will summarize the full year 2025 as well as Q4 2025 and Jakob 00:00:58.147 -- 00:01:00.730 will then present the group's financial performance. 00:01:00.730 -- 00:01:04.535 We will then proceed and comment on our performance in the two business areas, Life Science 00:01:04.535 -- 00:01:07.158 Solutions and Lab Automation. 00:01:07.158 -- 00:01:12.425 I will also comment on our R&D pipeline with our ongoing product development efforts. 00:01:12.425 -- 00:01:16.751 Additionally, I will highlight product launches made at SLAS, the Society of Lab Automation 00:01:16.751 -- 00:01:20.103 and Scr...